Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression-Reference-Cited by-同舟云学术

Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression

Published:2019-06-01 Issue:6 Volume:5 Page:833
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Nomura Hiroyuki¹,Aoki Daisuke¹,Michimae Hirofumi²,Mizuno Mika³,Nakai Hidekatsu⁴,Arai Masahide⁵,Sasagawa Motoi⁶,Ushijima Kimio⁷,Sugiyama Toru⁸,Saito Motoaki⁹,Tokunaga Hideki¹⁰,Matoda Maki¹¹,Nakanishi Toru¹²,Watanabe Yoh¹²,Takahashi Fumiaki¹³,Saito Toshiaki¹⁴,Yaegashi Nobuo¹⁵,

Affiliation:

1. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan

2. Division of Biostatistics, Department of Clinical Medicine, Kitasato University School of Pharmacy, Tokyo, Japan

3. Department of Gynecology, Aichi Cancer Center Hospital, Aichi, Japan

4. Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan

5. Department of Obstetrics and Gynecology, Kitasato University School of Medicine, Kanagawa, Japan

6. Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan

7. Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan

8. Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Iwate, Japan

9. Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan

10. Department of Gynecology, Tohoku University Hospital, Miyagi, Japan

11. Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo, Japan

12. Division of Obstetrics and Gynecology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan

13. Clinical Research, Innovation and Education Center, Tohoku University Hospital, Miyagi, Japan

14. Gynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

15. Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Miyagi, Japan

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/6/833/17667023/jamaoncology_nomura_2019_oi_190001.pdf

Reference35 articles.

1. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.;Colombo;Int J Gynecol Cancer,2016

2. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.;Creutzberg;Lancet,2000

3. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.;Keys;Gynecol Oncol,2004

4. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.;Blake;Lancet,2009

5. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.;Kong;Ann Oncol,2007

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis;Gynecologic Oncology;2024-02

2. A Modified Basophil Activation Test for the Clinical Management of Immediate Hypersensitivity Reactions to Paclitaxel: A Proof-of-Concept Study;Cancers;2023-12-13

3. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer;Clinical Therapeutics;2023-10

4. β‐catenin inhibitor ICG‐001 suppress cell cycle progression and induce autophagy in endometrial cancer cells;Journal of Cellular Physiology;2023-09-08

5. Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022) – Part 2 with Recommendations on the Therapy of Precancerous Lesions and Early-stage Endometrial Cancer, Surgical Therapy, Radiotherapy and Drug-based Therapy, Follow-up Care, Recurrence and Metastases, Psycho-oncological Care, Palliative Care, Patient Education, and Rehabilitative and Physiotherapeutic Care;Geburtshilfe und Frauenheilkunde;2023-08